Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab vs Adalimumab in Severe Takayasu Arteritis
NCT04300686Phase 4Recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Mar 2020
- Primary completion
- May 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of adalimumab in Takayasu arteritis (TAK), sponsored by Zhongshan Hospital, Fudan University. Started Mar 2020; status: recruiting.
02
Drugs
03
Conditions
Takayasu arteritis (TAK)
Beyond the preview
Go deeper on NCT04300686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04300686.